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Background: An E321G mutation in MYH1 was recently identified in Quarter Horses (QH) with
immune-mediated myositis (IMM) defined by a phenotype of gross muscle atrophy and myofi-
ber lymphocytic infiltrates.
Hypothesis/Objectives: We hypothesized that the MYH1 mutation also was associated with a
phenotype of nonexertional rhabdomyolysis. The objective of this study was to determine the
prevalence of the MYH1 mutation in QH with exertional (ER) and nonexertional (nonER)
rhabdomyolysis.
Animals: Quarter Horses: 72 healthy controls, 85 ER-no atrophy, 56 ER-atrophy, 167 nonER
horses selected regardless of muscle atrophy.
Methods: Clinical and histopathologic information and DNA was obtained from a database for
(1) ER > 2 years of age, with or without atrophy and (2) nonER creatine kinase (CK) ≥ 5000 U/L,
<5 years of age. Horses were genotyped for E321GMYH1 by pyrosequencing.
Results: The MYH1 mutation was present in a similar proportion of ER-no atrophy (1/56; 2%)
and in a higher proportion of ER-atrophy (25/85; 29%) versus controls (4/72; 5%). The MYH1
mutation was present in a significantly higher proportion of nonER (113/165; 68%) than con-
trols either in the presence (39/42; 93%) or in absence (72/123; 59%) of gross atrophy. Lym-
phocytes were present in <18% of muscle samples with theMYH1 mutation.
Conclusions and Clinical Importance: Although not associated with ER, the MYH1 mutation is
associated with atrophy after ER. The MYH1 mutation is highly associated with nonER regard-
less of whether muscle atrophy or lymphocytic infiltrates are present. Genetic testing will
enhance the ability to diagnoseMYH1 myopathies (MYHM) in QH.
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1 | INTRODUCTION
Immune-mediated myositis (IMM) is a well-recognized cause of rapid
onset muscle atrophy in Quarter Horse (QH)-related breeds.1,2 Atrophy
often follows exposure to environmental stimuli, such as respiratory
pathogens or vaccination, but the triggering factor remains unknown in
>40% of cases.1 An E321G mutation in MYH1 recently was found to be
strongly associated with IMM in QH.3 Horses with IMM were both
homozygous (My/My) and heterozygous (My/N) for theMYH1mutation.
The mutation was identified by means of a genome-wide association
Abbreviations: AST, aspartate transaminase; CK, creatine kinase; ER, exertional
rhabdomyolysis; GYS1, glycogen synthase 1; IMM, immune-mediated myositis;
MH, malignant hyperthermia; MYH1, myosin heavy chain 1; MYH2, myosin
heavy chain 2; NMDL, Neuromuscular Diagnostic Laboratory, Michigan State
University; nonER, nonexertional rhabdomyolysis; PSSM1, type 1 polysaccharide
storage myopathy; QH, Quarter Horse.
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study, with the phenotype for IMM defined as gross muscle atrophy and
lymphocytic myofiber infiltrates. Subsequent sequencing of genes within
the associated locus identified a missense mutation in a highly conserved
region of MYH1 that segregated with disease status.3 The MYH1 gene
encodes myosin heavy chain 2X, which is found in fast twitch type 2X
muscle fibers. In the absence of inflammation, the proportion of type 2X
muscle fibers in IMM muscle was within normal limits. However, in IMM
horses with gross muscle atrophy, lymphocytes infiltrated type 2X myofi-
bers and fewer type 2X fibers were present.3 The equine MYH1 muta-
tion is the first reported disease-causing mutation in MYH1 in any
species. The biological relevance of the E321G MYH1 mutation is
strengthened by the fact that glutamic acid (E) is highly conserved across
species (Sus, Bos, Homo, Oryctol, Rat, and Canis) and present in the cor-
responding position of the myosin heavy chain of type 2A, perinatal,
extraocular, embryonic, and cardiac/slow myosin in many species, includ-
ing the horse.4
The most common muscle disorder in QHs, rhabdomyolysis, shares
the characteristic of increased serum creatine kinase (CK) activity with
IMM.5 Causes of rhabdomyolysis range from toxins such as hypoglycin
A to genetic disorders such as type 1 polysaccharide storage myopathy
(PSSM1) and malignant hyperthermia (MH).6 However, in many cases of
rhabdomyolysis, the specific etiology is unrecognized.5 The features dis-
tinguishing rhabdomyolysis from IMM are the lack of rapid-onset muscle
atrophy and the absence of lymphocytic infiltrates in gluteal or epaxial
muscle biopsy samples.1,5,7 A diagnosis of IMM in horses could be
missed, however, when the primary presenting complaint is rhabdomy-
olysis because the most common muscle biopsy sample submitted for
evaluation of rhabdomyolysis is from the semimembranosus (SM) or
semitendinosus (ST) muscles. These muscles often lack lymphocytic infil-
trates in IMM horses.1,2
We hypothesized that the E321G MYH1 mutation would be prev-
alent in horses presenting with nonexertional rhabdomyolysis (nonER)
regardless of whether or not horses presented with or without muscle
atrophy. The purpose of our retrospective study was to determine if
the E321G MHY1 mutation associated with IMM also was associated
with the phenotype of rhabdomyolysis with or without gross muscle
atrophy and with or without lymphocytic infiltrates in muscle samples.
The objectives were: (1) to determine the prevalence of the MYH1
mutation in QH presenting with ER with or without gross muscle atro-
phy; (2) to determine the prevalence of the MYH1 mutation in young
QH presenting with nonER regardless of gross muscle atrophy; and
(3) to characterize the histopathologic findings in muscle biopsy sam-
ples of horses with rhabdomyolysis and theMYH1 mutation.
2 | MATERIALS AND METHODS
2.1 | Horses
2.1.1 | Controls
The prevalence of the MYH1 mutation in healthy QH was determined in
72 healthyQH,whichwere housed on farms across theUS, had no known
history ofmuscle disease and hadDNA available for testing (Table 1).
2.1.2 | Exertional rhabdomyolysis
Records and the sample repository of the Neuromuscular Diagnostic
Laboratory at Michigan State University (NMDL) were reviewed
between 2012 and 2017 to identify approximately 60 QH > 2 years
of age, negative for the GYS1 mutation, with a history of ER and DNA
available for testing. Exertional rhabdomyolysis was identified by
referring veterinarians based on clinical signs of muscle stiffness after
exercise and recorded on submission forms. Serum CK or AST activity
were not always reported on submission forms and were not used as
selection criteria for ER. Records of 948 ER horses also were searched
from 1995 to 2017 to identify QH with hair, buffy coat, or muscle
samples available for DNA extraction and that had a history of ER and
reported concurrent gross muscle atrophy. If available in the database,
the R309H GYS1 genotype for type 1 polysaccharide storage myopa-
thy (PSSM1) was noted and, if unavailable, horses were genotyped for
the GYS1 mutation.8 If available in the database, the genotype for the
C7360G RYR1 mutation for malignant hyperthermia was noted.9
2.1.3 | Nonexertional rhabdomyolysis
Records and the sample repository of the NMDL were reviewed from
1995 to 2017 to identify all QH < 5 years of age that had a history
consistent with nonER, documented serum CK activity ≥5000 U/L
and hair, buffy coat, or muscle samples available for DNA extraction.
If available in the database, the R309H GYS1 genotype for PSSM1
was noted and, if unavailable, horses were genotyped for the GYS1
mutation.8 All horses with the GYS1 mutation were excluded from fur-
ther analysis to ensure that PSSM1 did not contribute to nonER. If
TABLE 1 Mean ages and genders of horses with exertional (ER) and nonexertional rhabdomyolysis (nonER) grouped according to whether or not
they presented with muscle atrophy
GYS1 status Mean age years (SD) Mares Geldings Stallions Not specified
Control (N = 72) Both 8.3  4.9 44 26 1 1
ER horses (N = 141) 8.2  4.2 61 69 4 7
Atrophy (N = 23) Positive 7.5  4.6ab 10 13 0 0
Atrophy (N = 62) Negative 7.5  4.0a 22 34 3 3
No atrophy (N = 56) Negative 9.8  3.9b 29 22 1 4
NonER (N = 165) 1.5  1.2 92 34 35 4
Atrophy (N = 42) Negative 1.3  1.0c 22 10 10 0
No atrophy (N = 123) Negative 1.6  1.3c 70 24 25 4
Horses with ER did not have any restrictions on age for inclusion whereas nonER horses were selected with an upper age-limit of 4 years of age. Different
superscripts indicate significant differences within columns where ER and for nonER analyzed separately. Abbreviation: GYS1, glycogen synthase 1.
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available in the database, the genotype for C7360G RYR1 was noted
and, if glycogen depletion had been noted in the histochemical evalua-
tion, analysis was performed for C7360G RYR1.9 Clinical signs
recorded by the referring veterinarian were tabulated and compared
between genotypes.
2.2 | Histopathology
The sample repository was reviewed to identify those horses that had
muscle biopsy samples of the gluteus, epaxial, SM, or ST muscles sub-
mitted for evaluation. Archived histologic slides from ER with muscle
biopsy samples and all nonER horses were re-evaluated blinded to
genotype. Slides stained with hematoxylin and eosin (HE), periodic
acid Schiffs (PAS), and amylase-PAS were scored for the presence of
fiber size variation, anguloid atrophy, internalized myonuclei, acute
myofiber degeneration (loss of striations without cellular infiltrate),
macrophage infiltrates, myofiber lymphocytic infiltrates, mononuclear
cell vascular cuffing, abnormal polysaccharide, and PAS depletion of
small or large myofibers. The scoring system used at ×20 magnifica-
tion to grade the above features was based on: 0 = not present,
1 = present in approximately 10% of fibers in the biopsy sample,
2 = present in approximately 11-25% of fibers in the sample, and
3 = present in >25% of fibers in the sample. Periodic acid Schiffs
stains were scored for the intensity of PAS stain as: absent (0), light
(1), moderate (2), or darkly stained (3). Scores were compared across
genotypes in different horses within the same muscle group. Scores
also were compared between muscle groups within a set of horses
that had both gluteal/epaxial and SM/ST muscles sampled.
Myosin ATPase staining was performed in 1 batch of gluteal mus-
cle samples from 10 horses homozygous for the MYH1 mutation and
9 normal/normal (N/N) horses. Samples were preincubated for
5 minutes by an acid pH (4.4), which in our laboratory consistently
identifies muscle fiber types 1, 2A, and 2X.10 Muscle fiber type com-
position was determined by counting the fiber types of at least
250 myofibers. Type 2 fiber types were further evaluated in 2 N/N
and 3 MYH1 homozygotes with immunofluorescent (IF) antibody
staining for myosin heavy chains as previously described.3,11 Primary
antibodies used included type 2A IgG at 1:6 (A4.74 DSHB) and for
both type 2A and 2X IgG at 1:10 (NCL-MHCf Leica Biosystems, Wet-
zlar, Germany). Sections were examined by a fluorescence microscope
(Olympus, Tokyo, Japan) with filters designed for each of the different
emitting wavelengths.
Images were captured and pseudocolored composites generated.
2.3 | Genotyping
2.3.1 | DNA isolation
The DNA was isolated from hair bulbs, buffy coat, whole blood, or
muscle tissue by Gentra Puregene Kits (Qiagen; Germantown, Mary-
land) and quantified to ensure ≥10 ng/μL of DNA was available with a
260/280 ratio of ≥1.8 and ≤ 2.2. DNA for PCR reactions was diluted
to 35  25 ng/μL.
2.3.2 | Polymerase chain reaction
Thermocycling was carried out by recombinant AmpliTaqs Gold poly-
merase (Applied Biosystems, Foster City, California) in a PTC-200
thermocycler (MJ Research Inc., Watertown, Massachusetts). Each
50 μL PCR reaction contained 19 μL Platinum Green PCR 2X MM
reagent (Invitrogen, Carlsbad, California), 1 μL of each the forward and
reverse primers, 200  25 ng of purified chromosomal DNA, with the
remaining volume made up with sterile double-distilled
H2O. Amplification was performed under the following conditions:
the initial denaturation temperature was set at 95C for 10 minutes
and the subsequent denaturation at 94C for 30 seconds, annealing at
46C for 30 seconds, and a primer extension at 72C for 30 seconds
for 40 cycles with a final extension time of 10 minutes at 72C. The
PCR products were run on a 1.0% agarose gel and stained with ethi-
dium bromide.
2.3.3 | Pyrosequencing
Forward, reverse, and sequencing primers were designed by Pyrose-
quencing Assay Design Software (version 1.0; Biotage, Uppsala, Swe-
den) and biotin labeled, and regular primers were ordered from
Integrated DNA Technologies (IDT), Skokie, Illinois. Forward (50-
TAAAAAGCTGCATGTGTA-30) and reverse (50-AAAACACATACCCT-
GAAT-30) primers were used to amplify a 159-bp region (ECA11:
52993805-52993963) containing a coding single nucleotide polymor-
phism (SNP) (T/C, ECA11: 52993877) of the MYH1 mutation. The
resulting amplicon was annealed with the sequencing primer (5’-
TGCTGGGGACTGTGA-30) and relative expression of each allele was
determined by pyrosequencing following manufacturer's protocol
(Qiagen; Germantown, Maryland). All sample plates were analyzed
with suitable positive controls and template control containing no
DNA, with resulting data manually evaluated to determine genotypes.
2.4 | Data analysis
Normality was tested via a Shapiro-Wilk normality test. A 1-way anal-
ysis of variance (ANOVA) was used to compare ages of horses. A chi-
square test was used to compare the genotypes of random QH con-
trols, ER and nonER horses with specific clinical signs as well as to
compare the number of horses with lymphocytic infiltrates and large
myofiber glycogen depletion. Scores for muscle histopathology were
compared by Mann-Whitney test. Serum CK and AST activities in
nonER horses were log transformed to normalize data and compared
by one-way ANOVA. Statistical analyses were performed in GraphPad
Prism 7 (GraphPad Prism version 7, GraphPad Software, La Jolla, Cali-
fornia, www.graphpad.com). Results are presented as mean and stan-
dard deviations (SD). Significance was set at P < .05.
3 | RESULTS
There were 72 control horses, similar in age to ER horses (Table 1).
Fifty-six ER horses without atrophy and 85 ER horses with atrophy
(62 GYS1 negative, 23 GYS1 positive) were included in the study
(Table 1). Among GYS1-animals, horses with muscle atrophy were sig-
nificantly younger than horses without muscle atrophy (P < .006).
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There were 165 nonER horses, 42 with atrophy and 123 without atro-
phy (Table 1). The mean age of nonER horses was only 1 year despite
inclusion criteria that specified all nonER horses <5 years of age.
Control genotypes: The MYH1 mutation was present in 5% of
controls (4/72).
3.1 | Exertional rhabdomyolysis
3.1.1 | ER genotypes
The MYH1 mutation was present in 2% (1/56) of ER horses without
gross muscle atrophy (Figure 1). The MYH1 mutation was present in
29% (25/85) of ER with atrophy including both those GYS1+ (5/23;
22%) and GYS1- (20/62; 32%), which was a significantly higher pro-
portion than controls (P < .001; Figure 1). The mutation for C7360G
RYR1 was not found in any of the 30 ER horses tested.
3.1.2 | ER histopathology
Slides from 61 muscles were available for evaluation. Only 7 of these
horses (8 muscle samples) were homozygous or heterozygous for the
MYH1 mutation (2 gluteal/epaxial and 6 SM/ST) and no significant dif-
ferences were found when histopathology scores for MYH1 homozy-
gotes (My/My) or heterozygotes (My/N) horses combined were
compared to N/N horses.
3.2 | Nonexertional rhabdomyolysis
3.2.1 | NonER genotypes
Significantly, more nonER horses (111/165; 67%) possessed the
E321G MYH1 mutation than controls (P < .001). NonER horses were
both homozygous (75%) and heterozygous (25%) for the MYH1 muta-
tion (Figure 1). The MYH1 mutation was highly prevalent in nonER
horses regardless of atrophy (39/42, 93% with atrophy; 72/123, 59%
without atrophy). The mutation for C7360G RYR1 was not present in
any of the 81 nonER horses tested.
3.2.2 | NonER clinical signs
When specifically evaluating nonER horses with the MYH1 mutation,
65% (72/111) were not reported to have gross muscle atrophy and
35% (39/111) were reported to have atrophy. The MYH1 mutation
increased the risk for muscle atrophy 12× in nonER horses (P < .001:
OR 12.3). A history of fever was significantly more common in nonER
horses with the MYH1 mutation (P < .038; odds ratio [OR], 7.6).
Weakness (P < .003; OR, 0.06) was less common in horses with the
MYH1 mutation compared to nonER horses without the mutation.
The frequencies of recumbency, swollen muscles, stiffness, colic, or
history of infection were not significantly different between nonER
horses with and without the MYH1 mutation. Serum CK activities
were markedly increased in nonER with maximum activities >1 million
U/L in all genotypes (Figure 2). Log-transformed serum CK (P < .006)
and AST (P < .001) activities were significantly higher inMYH1 hetero-
zygotes and homozygotes compared to nonER horses without the
mutation, with no significant differences between homozygotes and
heterozygotes.
3.2.3 | NonER histopathology
Slides from 153 nonER muscle samples were available for evaluation.
The gluteal/epaxial muscles and the SM/ST muscles of My/My horses
had significantly higher histopathologic scores for fiber size variation,
anguloid atrophy, and centrally displaced myonuclei than N/N nonER
horses (Figures 3 and 4, Table 2). Scores for acute myofiber degenera-
tion, lymphocytic infiltrates, and macrophages were significantly
higher in gluteal/epaxial muscles of My/My horses than in N/N nonER
horses with no significant difference for these features between
genotypes in SM/ST muscles (Table 2). This finding agrees with com-
parisons of the 2 muscle groups within the same MYH1 homozygotes
where the gluteal/epaxial muscles had significantly higher scores for
acute necrosis, macrophages, and lymphocytes than did the SM/ST
muscles (Table 3). Each individual score for heterozygotes was inter-
mediate between My/My and N/N nonER horses but not statistically
different from My/My or N/N (Figure 3, Table 2). Fewer than 18% of
horses with the MYH1 mutation had lymphocytic infiltrates in myofi-
bers (Table 4) and the frequency of samples with lymphocytic
FIGURE 1 The distribution of MYH1 genotypes in nonER horses with
atrophy (nonER A), nonER horses without atrophy (nonER no A), ER
horses without atrophy (ER no A), ER horses with atrophy positive for
PSSM1 (ER PSSM1 A), ER with atrophy, negative for PSSM1 (ER A)
and controls (random QH). Significantly, more nonER horses and ER
horses with atrophy possessed theMYH1 mutation (My/My and
My/N) compared to random QH
FIGURE 2 Serum CK and AST activities in individual nonER horses
homozygous (My/My), heterozygous (My/N), or unaffected (N/N) for
the MYH1 mutation. Different letters indicate significant differences
within CK and AST
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infiltrates did not differ between horses with and without the MYH1
mutation (Table 4). Total myopathic scores were significantly higher in
My/My and My/N heterozygotes for gluteal/epaxial and SM/ST
(Table 2).
No significant differences were found in scores for PAS stain
intensity, glycogen depletion in small myofibers, or abnormal cytoplas-
mic glycogen between My/My, My/N, or N/N nonER horses. How-
ever, significant differences were identified in scores for glycogen
depletion in large myofibers of the gluteal/epaxial muscles across
genotypes, with My/My horses having significantly higher scores than
N/N nonER horses (Figure 4, Table 2). The number of horses with
total glycogen depletion in large fibers of SM/ST also was higher in
My/My versus N/N nonER horses (Table 4). Subjectively, the largest
fibers were typical type 2X fibers in N/N nonER horses, whereas in
My/My horses, the largest fibers were typically type 2A fibers
(Figure 4).
In myosin, ATPase stains of N/N horses, 3 distinct fiber types
were readily distinguished (Figure 4), with the mean fiber type compo-
sition being type 1:8  9%, type 2A: 24  11% and type 2X:
67  12%. Three distinct fiber types were apparent in 4/10 My/My
horses, with highly variable fiber type compositions of type
1:13  17%, type 2A: 49  26%, and type 2X: 43  21%. In 6/10
nonER MYH1 homozygotes, it was difficult to discern type 2A and
type 2X fibers ATPase stains (Figure 4). By IF staining for type 2 myo-
sin heavy chains, type 2 fiber subtypes, 2A, 2AX, and 2X were readily
apparent in My/My and N/N horse muscle.
4 | DISCUSSION
The major finding in our study was the strong association between
the E321G MYH1 mutation and nonER in QH-related breeds. In total,
67% of nonER QH possessed the MYH1 mutation compared to 5% of
randomly selected healthy QH. Rhabdomyolysis in the nonER horses
was severe with median serum CK activities above 30 000 U/L and
maximal activities of over 1 million U/L, much higher than median
activities previously reported for IMM.1 Neither PSSM1, which affects
FIGURE 3 Histopathological scores for skeletal muscle fiber type
variation, anguloid atrophy, acute myofiber degeneration (myodegen),
macrophages (macroph), and lymphocytes (lymph) in large myofibers
in the gluteal muscle of horses homozygous (My/My), heterozygous
(My/N), or unaffected (N/N) for theMYH1 mutation. *P < .05,
**P < .01, ***P < .001
FIGURE 4 Glycogen depletion patterns (A-D) and muscle fiber types identified by either myosin ATPase (E,G) or IF myosin heavy chain antibody
staining (F,H). Myosin ATPase staining of N/N and My/My horses was performed at the same time. A, Three distinct fiber type (1, 2A, and 2X)
with the largest fibers being type 2X in an N/N horse. Myosin ATPase stain (pH 4.4) 20X. B, Complete depletion of muscle glycogen in type 1 and
2X myofibers of the N/N horse with nonexertional rhabdomyolysis. PAS 20X. C, Three distinct fiber types with anguloid atrophy of type 2X
myofibers in an My/My horse. Type 2X fibers show anguloid atrophy (arrow) and the largest sized fibers are type 2A. Myosin ATPase stain
(pH 4.4) 20X. D, Glycogen depletion is present in type 1 and 2A myofibers of the MY/My horse. PAS 20X. E, Type 2A and 2X fiber types are
readily distinguished in myosin ATPase stains of an N/N horses with nonER. Myosin ATPase (pH 4.4) 20X. F, Type 2A, 2X and a few 2AX fiber
types are apparent in the N/N non ER horse. Type 1 fibers were distinguished by cross-matching with black stained type 1 fibers in the ATPase
stain. IF stain 20X. G, This My/My nonER horse only had two distinct fiber types (1 and 2) in the myosin ATPase stain. Asterisks represent the
type 2A fibers that were identified by serial IF antibody stain. A type 2X fiber identified by IF stain is labeled 2X. Note the generally smaller fiber
sizes compared to the control. myosin ATPase (pH 4.4) 20X. H. Type 2A and 2X fibers are distinguished in IF stain of the My/My horse in G. Type
1 fibers were identified by cross-matching black stained type 1 fibers in the ATPase stain with corresponding fibers in the serial IF stain
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11% of QH, nor MH which affects <1% of QH (16/7334 tested
2008-2014; personal observation), were likely causes of nonER in our
study because PSSM1 horses were excluded from the analysis and
genetic testing was negative for MH in all horses tested.12
The E321G MYH1 mutation appeared to be dominant with
respect to rhabdomyolysis because both heterozygotes and homozy-
gotes had serum muscle enzyme activities that were significantly
higher than those reported for horses with rhabdomyolysis because of
other causes. The MYH1 mutation appeared to have a codominant
effect on muscle histopathology in that nonER homozygotes had
higher total histopathologic scores than heterozygotes in both glu-
teal/epaxial and SM/ST muscles and scores for each histopathologic
characteristic in heterozygotes were intermediate between homozy-
gotes and N/N horses. Unlike PSSM1 and MH, exercise was not a
trigger for rhabdomyolysis in horses with the MYH1 mutation, with
only 2% of horses with ER and normal muscle mass possessing the
MYH1 mutation.9,13
Quarter Horses with gross muscle atrophy were highly likely to
possess the MYH1 mutation with 93% of nonER QH with atrophy
being My/My or My/N and 29% of atrophied ER horses also were
My/N. Quite unexpectedly, however, nearly 60% of nonER horses
with the MYH1 mutation did not have gross muscle atrophy, the most
common clinical sign reported for IMM.1,14 It is possible that atrophy
developed later after muscle biopsy in some horses or that horses
died before developing atrophy. Alternatively, moderate to severe
rhabdomyolysis may be an early if not sole myopathic feature of
nonER in some QH with the MYH1 mutation. Our results therefore
suggest that testing for the MYH1 mutation is indicated in QH with
nonER whether or not atrophy is present and in ER horses that
develop muscle atrophy.
One of the previously reported features of muscle from IMM
horses with the MYH1 mutation is immune-mediated lymphocytic
destruction of type 2X muscle fibers, which comprise at least 60% of
fibers in healthy gluteal muscle.3 Both innate and adaptive immunity
could trigger IMM. The innate immune response could drive reactivity
TABLE 2 Mean (SD) histopathologic scores in gluteal/epaxial muscles and semimembranosus (SM)/semitendinosus (ST) muscles in horses with
nonexertional rhabdomyolysis (nonER) and exertional rhabdomyolysis (ER)
Muscle N Genotype
Fiber size
variation
Anguloid
atrophy
Internalized
myonuclei
Acute
myodegen. Macroph. Lymph.
Large fiber
glycogen
depletion Total score
NonER
Glut/
Epaxial
24 My/My 1.7  0.7a 1.5  0.8a 0.6  0.8a 1.3  1.0a 1.7  1.3a 1.1  1.1a 1.4 1.2a 11.9  4.1a
Glut/
Epaxial
17 My/N 1.4 0.8ab 0.7  0.9ab 0.1  0.5ab 0.2  0.6ab 0.6  1.0ab 0.2  0.5ab 1.1  1.4ab 6.4  2.8b
Glut/
Epaxial
8 N/N 0.9  0.4b 0.5  0.6b 0.0  0.0b 0.0  0.0b 0.3  0.5b 0.0  0.0b 0.4  1.1b 5.0  2.8b
SM/ST 41 My/My 1.5  0.7a 1.2  0.8a 0.6  0.8a 0.2  0.7 0.4  0.9 0.2  0.7 1.1  1.3 8.0  4.8a
SM/ST 33 My/N 1.3  0.5ab 0.7  0.8ab 0.1  0.2ab 0.2  0.6 0.2  0.7 0.0 0.0 0.8  1.1 5.5  2.8b
SM/ST 30 N/N 1.1  0.5b 0.5  0.7b 0.1  0.4b 0.2  0.5 0.2  0.6 0.1 0.2 0.8  1.0 5.6  2.5b
ER
SM/ST 3 My/My 1.3  0.3 0.8  0.8 1.0  0.9 0.0  0.0 0.0  0.0 0.0  0.0 0.0  0.0 5.5  2.7
SM/ST 4 My/N 1.5  1.3 0.9  1.0 0.5  0.6 0.0  0.0 0.0  0.0 0.0  0.0 0.0  0.0 6.4  4.2
SM/ST 46 N/N 1.4  0.6 0.9  0.9 0.4  0.7 0.0  0.1 0.1  0.3 0.0  0.2 0.1  0.3 6.5  3.4
Scores ranged from 0 to 3. Different letters indicate significant differences (P < .05) in scores across genotypes within the same muscle. Abbreviations:
nonER, nonexertional rhabdomyolysis; ER, exertional rhabdomyolysis; Myodegen, myodegeneration; macroph., macrophage; lymph, lymphocytes.
TABLE 3 Mean (SD) histopathologic scores in paired gluteal/epaxial muscles and semimembranosus/semitendinosus muscles obtained from
the same horses with nonexertional rhabdomyolysis (nonER)
Muscle N Genotype
Fiber size
variation
Anguloid
atrophy
Internalized
myonuclei
Acute
mydegen. Macroph. Lymph.
Large fiber
glycogen
depletion
NonER
Glut/
Epaxial
19 My/My 1.6  0.7 1.5  0.7 0.7  0.7 1.2  0.9a 1.4  1.3a 0.9  0.9a 1.3  1.1a
SM/ST 19 My/My 1.5  0.5 1.3  0.6 0.8  0.8 0.3 0.8 b 0.3  0.8b 0.2  0.7b 1.4  1.4b
Glut/
Epaxial
7 My/N 1.6  0.8 1.0  0.9 0.2  0.6 0.4 0.7 1.0  1.2 0.3  0.7 1.3  1.4
SM/ST 7 My/N 1.3  0.5 0.6  1.0 0.3  0.5 0.0  0.0 0.0  0.0 0.0  0.0 0.1  0.2
Glut/
Epaxial
5 N/N 1.0  0.0 0.3  0.4 0.0  0.0a 0.0  0.0 0.2  0.4 0.0  0.0a 0.0  0.0
SM/ST 5 N/N 0.9  0.5 0.8  0.4 0.4  0.3b 0.4  0.4 0.6  0.5 0.4  0.3b 0.8  0.6
Scores ranged from 0 to 3. Different letters indicate significant differences (P < .05) in scores between muscles within the same genotype
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to self and affect the type of adaptive immune response that occurs
when the mutant form of type 2X myosin heavy chain is released from
myofibers after muscle damage (ER, trauma, and vaccination).14,15
Shared epitopes among bacteria, such as the M protein of group A
Streptococcus spp. and the altered myosin in horses with the MYH1
mutation are potential instigators of an adaptive immune response.3,16
Of note, 2 young horses in our study that were homozygous and het-
erozygous for MYH1 were previously reported to have fatal S. equi-
associated rhabdomyolysis.17 This observation suggests that the
MYH1 mutation may be the cause of previously reported S. equi-
associated rhabdomyolysis in horses. Agents such as S. equi zooepide-
micus, C. pseudotuberculosis, equine herpes virus, and equine influenza
virus previously have been associated with triggering IMM and there-
fore potentially could be triggers for rhabdomyolysis in QH with the
MYH1 mutation through the innate response either to primary muscle
damage or by adaptive immunity.14 Atrophy, fever, and infection in
the presence of rhabdomyolysis appear to be strong indicators to per-
formMYH1 genetic testing in QH.
A confounding factor in connecting rhabdomyolysis to cell-
mediated destruction of type 2X fibers in our study was the fact that
<18% of horses with the MYH1 mutation had lymphocytic infiltrates
in muscle biopsies. The lack of lymphocytic infiltrates in many muscle
samples suggests that either the cell-mediated immune reaction in
skeletal muscle was not captured in the muscle biopsies evaluated or
that an immune-mediated mechanism is not entirely responsible for
rhabdomyolysis. The SM muscle alone was sampled in 48% of nonER
horses and inflammatory infiltrates are more likely to be present in
epaxial and gluteal muscles in IMM horses.2 Therefore, the selection
of the SM muscle for biopsy could have decreased the ability to iden-
tify lymphocytic infiltrates. In 59% percent of horses with the MYH1
mutation, however, gluteal/epaxial biopsy samples did not contain
lymphocytic infiltrates. Timing of biopsies could have affected inflam-
matory infiltrates such that biopsies taken several weeks after the
onset of atrophy potentially lacked inflammatory cells. Smaller needle
biopsies of epaxial and gluteal muscles also could have resulted in
missed areas of inflammation. Alternatively, other mechanisms may
exist for rhabdomyolysis in horses with the MYH1 mutation.
Some myopathies associated with mutations in MYH2, encoding
type 2A myosin heavy chain, exist in humans and are not believed to
have an immune-mediated basis.18–20 Weakness rather than rhabdo-
myolysis are primary presenting complaints in these cases. Histopath-
ologic findings in late onset dominant MYH2 mutations overlap
features of equineMYH1 myopathy in our study and include increased
variation in muscle fiber sizes, anguloid myofiber atrophy and centrally
located nuclei. Type 2A fiber are either atrophic with dominant MYH2
mutations or absent in children with recessive deletions.18,21 Atrophic
and atrophied type 2X fibers were present in some horses with MYH1
myopathy, suggesting the mutation itself may be a cause of atrophy.
Mutations in MYH2 in humans, however, have not been associated
with rhabdomyolysis.
Our study provided an indication the MYH1 mutation affect the
activity of the myosin ATPase enzyme. The ATPase enzyme is located
in the globular head of type 2X myosin near the site of the MYH1
mutation.3 Modeling suggests that the E321G MYH1 mutation
decreases contact between the SWITCH1 and helix 1 domains of the
myosin 2X globular head and decreases stability of the protein.3 This
altered protein interaction could affect the myosin ATPase enzyme,
which is commonly used in histochemical assays to detect fiber types.
In our study, IF staining and myosin ATPase assays both differentiated
2A and 2X fiber types consistently in N/N horses. In 60% of horses,
homozygous for the MYH1 mutation however, myosin ATPase stain-
ing failed to clearly distinguish 2A and 2X, even though the 2A and 2X
fibers were identified by IF antibody staining. All samples stained with
myosin ATPase were handled in the same fashion in that they were
shipped overnight to the laboratory before freezing. The difference in
staining of fast twitch fibers by ATPase activity in N/N and My/My
horses suggests that the functional effect of the MYH1 mutation on
the speed of contraction and myosin ATPase enzyme should be fur-
ther investigated.
Complete depletion of glycogen is an unusual feature of equine
muscle biopsy samples. Approximately 30% of nonER MYH1 homozy-
gotes showed marked glycogen depletion in large myofibers of both
epaxial/gluteal and SM/ST samples. Glycogen depletion also was pre-
sent in 7-13% of N/N horses with rhabdomyolysis. Glycogen deple-
tion is a feature of episodes of MH in which increased myoplasmic
calcium increases actin/myosin interaction, markedly increases ATP
consumption and leads to marked anaerobic glycolysis and glycogen
degradation.9,22 Malignant hyperthermia was unlikely in the horses in
our study because none of the horses tested, including those with gly-
cogen depletion scores of 3, had the equine mutation for MH. Based
on the location of the MYH1 mutation in the myosin 2X globular head
near the ATP binding pocket, and the inconsistent demonstration of
myosin ATPase activity in type 2X fibers, one could postulate a poten-
tial role for abnormal actin/myosin interaction in a fashion similar to
MH, resulting in excessive glycogen metabolism and rhabdomyolysis
in the non ER horses.3 Determining whether there is a potential role
of altered myosin ATPase enzyme activity and excessive glycogen
metabolism in the development of nonER in horses with MYH1 is an
intriguing possibility that requires further exploration.
In conclusion, the E321G MYH1 mutation is strongly associated
with nonER in QH-related breeds whether or not generalized muscle
atrophy is present. Because most nonER horses with the MYH1
TABLE 4 Frequency of large fiber glycogen depletion and
lymphocytic infiltrates in gluteal/epaxial (Glut/epax) muscles and
semimembranosus/ semitendinosus (SM/ST) muscles of horses
genotyped for theMYH1 mutation
Muscle
N
total Genotype
Lymphocytic
infiltrates N (%)
Large fiber
glycogen
depletion
N (%)
Glut/Epaxial 24 My/My 3 (12.5) 7 (29.2)
Glut/Epaxial 17 My/N 3 (17.6) 5 (29.4)
Glut/Epaxial 8 N/N 0 (0) 1 (12.5)
SM/ST 41 My/My 4 (9.8) 11 (26.8)a
SM/ST 33 My/N 0 (0) 2 (6.1)b
SM/ST 30 N/N 3 (10.0) 2 (6.7)b
Letters indicate significant differences in glycogen depletion within the
same muscle. No differences were found in the frequency of lymphocytes
across genotypes. Different letters indicate significant differences
(P < .05) in scores across genotypes within the same muscle
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mutation did not present with muscle atrophy or have lymphocytic
infiltrates in muscle biopsy samples, we suggest that the term MYH1
myopathy (MYHM) be applied specifically to horses with atrophy or
rhabdomyolysis that test positive for the MYH1 mutation. This term
rather than IMM for horses with this genetic mutation eliminates the
confusion about whether the underlying mechanism for rhabdomyoly-
sis and atrophy is immune-mediated and distinguishes those inflam-
matory or immune-mediated myopathies that are not caused by the
MYH1 mutation.
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